– Ad-RTS-hIL-12 plus 20 mg veledimex (Controlled IL-12 platform) determined to be the preferred dose with low-dose steroids to treat adult patients with recurrent glioblastoma – – Median overall survival for Controlled IL-12 in patients receiving low-dose steroids was 17.8 months – – Increased
– FDA Cleared IND for Phase 1 Trial of Sleeping Beauty TCR-T cell therapy for patients with solid tumors at the National Cancer Institute (NCI) – – Exclusive license from NCI for library of T-cell receptors (TCRs) targeting neoantigens in the hotspots KRAS, p53 and EGFR – – Balance sheet
BOSTON , Aug. 08, 2019 (GLOBE NEWSWIRE) -- Ziopharm Oncology , Inc. (“Ziopharm” or “the Company”) (Nasdaq: ZIOP), today announced the European Medicines Agency (EMA) Committee for Orphan Medicinal Products (COMP) adopted a positive opinion recommending Ad-RTS-hIL-12 plus veledimex (Controlled
BOSTON , July 30, 2019 (GLOBE NEWSWIRE) -- Ziopharm Oncology , Inc. (Nasdaq:ZIOP) today announced that management will host a conference call and webcast on Thursday, August 8 , at 8:30 a.m. ET to provide a corporate update and discuss financial results for the second quarter ended June 30 , 2019.
Provides capital to fund operations into 2021; warrant exercise in advance of November 2023 expiration BOSTON , July 29, 2019 (GLOBE NEWSWIRE) -- Ziopharm Oncology , Inc. (“Ziopharm”) (Nasdaq: ZIOP), today announced that it has entered into an agreement with existing investors for the exercise of
Joins from Vertex Pharmaceuticals; Served as global Head of Corporate Finance BOSTON , July 24, 2019 (GLOBE NEWSWIRE) -- Ziopharm Oncology , Inc. (“Ziopharm” or “the Company”) (Nasdaq:ZIOP), a clinical stage immuno-oncology company developing next-generation cell and gene therapies, today announced
– Dr. Deniger joins from National Cancer Institute to lead Ziopharm’s non-viral T-cell program targeting neoantigens for personalized immunotherapy of solid tumors – BOSTON , July 03, 2019 (GLOBE NEWSWIRE) -- Ziopharm Oncology , Inc. (“Ziopharm” or “the Company”) (Nasdaq:ZIOP), today announced Drew
Phase 2 trial will enroll approximately 30 patients and evaluate both safety and efficacy BOSTON , June 27, 2019 (GLOBE NEWSWIRE) -- Ziopharm Oncology , Inc. (“Ziopharm” or “the Company”) (Nasdaq:ZIOP) today announced the initiation of a phase 2 clinical trial evaluating Controlled IL-12
– Enrollment completed in third cohort of dose-escalation study at leading brain cancer hospitals in US; Investigators indicate interest in expanding study – BOSTON , June 26, 2019 (GLOBE NEWSWIRE) -- Ziopharm Oncology , Inc. (“Ziopharm” or “the Company”) (Nasdaq:ZIOP) today announced completion of
Operations Management Leader for Immunex, Dendreon; Co-Founder and Chief Strategy Officer of Vineti BOSTON , June 17, 2019 (GLOBE NEWSWIRE) -- Ziopharm Oncology , Inc. (“Ziopharm” or “the Company”) (Nasdaq:ZIOP), today announced Heidi Hagen , an experienced and entrepreneurial biotechnology
